CELGENE CORPORATION AND BLUEBIRD BIO ANNOUNCE BB2121 ANTI-BCMA CAR-T CELL THERAPY HAS BEEN GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM FDA AND PRIME ELIGIBILITY FROM EMA FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA da Luca Bonadei | Nov 16, 2017 | Business“http://www.businesswire.com”
CELGENE CORPORATION AND BLUEBIRD BIO ANNOUNCE BB2121 ANTI-BCMA CAR-T CELL THERAPY HAS BEEN GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM FDA AND PRIME ELIGIBILITY FROM EMA FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA da Luca Bonadei | Nov 16, 2017 | Business“http://www.businesswire.com”